Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells

Weyland, M; Griveau, Audrey; Bejaud, Jérôme; Benoit, Jean‐Pierre; Coursaget, Pierre; Garcion, Emmanuel

doi:10.1016/j.ijpharm.2013.06.013

Cited by 17 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All the systems were treated with drugs and nanoparticles diluted with serum free N1 supplemented medium. Serum free N1 supplemented medium was prepared with DMEM with amino acids, 1% antibiotics (10,000 units penicillin, 10 mg streptomycin, 25 μg amphotericin B/mL solubilized in an appropriate citrate buffer), 1% HEPES buffer, 1% NEAA (Non Essential Amino Acid) 100X, 1% sodium pyruvate, 1% N1 medium supplement 100X [33,34]. Cell viability reduction assay was performed using CellTiter 96® AQueous One Solution cell proliferation assay kit containing a tetrazolium compound [3- Evaluation of HMGB1 secretion and ATP release upon incubation of DACHPt-loaded nanoparticles with B6KPC3 cells B6KPC3 cells were plated and treated as described above, with increasing concentrations of DACHPt-loaded NP, oxaliplatin and DACHPt water solution during 24 h. Blank NP were also tested as a control.…”

Section: Viability Studies On B6kpc3 A549 and Ht-29 Cell Linesmentioning

confidence: 99%

Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery

Matha

Lollo

Taurino

et al. 2020

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

This work provides insights over a novel biodegradable polymeric nanosystem made of hyaluronic acid and polyarginine for diaminocyclohexane-platinum (DACHPt) encapsulation. Using mild conditions based on ionic gelation technique, monodispersed blank and DACHPt-loaded nanoparticles with a size of around 200 nm and negative  potential (-35 mV) were obtained. The freeze-drying process was optimized to improve the stability and shelf-life of the developed nanoparticles. After reconstitution, nanoparticles maintained their size showing an association efficiency of around 70 % and a high loading efficacy (8%). In vitro cytotoxicity studies revealed that DACHPt-loaded nanoparticles had a superior anticancer activity compared with oxaliplatin solution. The IC50 was reduced by a factor of two in HT-29 cells (IC50 39 µM vs 74 µM, respectively), and resulted almost 1.3 fold lower in B6KPC3 cells (18µM vs 23µM respectively). Whereas toxic effects of both drugformulations were comparable in the A549 cell line (IC50 11 µM vs 12 µM). DACHPt-loaded nanoparticles were also able to modulate immunogenic cell death (ICD) in vitro. After incubation with B6KPC3 cells, an increase in HMGB1 (high-mobility group box 1) production associated with ATP release occurred. Then, in vivo pharmacokinetic studies were performed after intravenous injection (IV) of DACHPt-loaded nanoparticles and oxaliplatin solution in healthy mice (35.9 µg of platinum equivalent/mouse). An AUC six times higher (24 h*mg/L) than the value obtained following the administration of oxaliplatin solution (3.76 h*mg/L) was found. C max was almost five times higher than the control (11.4 mg/L for NP vs 2.48 mg/L). Moreover, the reduction in volume of distribution and clearance clearly indicated a more limited tissue distribution. A simulated repeated IV regimen was performed in silico and showed no accumulation of platinum from the nanoparticles. Overall, the proposed approach discloses a novel nano-oncological treatment based on platinum derivative with improved antitumor activity in vitro and in vivo stability as compared to the free drug.

show abstract

Section: Viability Studies On B6kpc3 A549 and Ht-29 Cell Linesmentioning

confidence: 99%

Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery

Matha

Lollo

Taurino

et al. 2020

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

show abstract

“…For example, tests involving the herpes simplex virus [7], or the Sendai virus, particularly due to their tropism for the respiratory tract [8] are still running for use in CF applications. However, many problems persist in terms of bioproduction, immunogenicity related to their readministration [9], safety, reproducibility, and potential oncogenicity. These drawbacks have led to the development of alternatives, such as synthetic gene delivery systems.…”

Section: Introductionmentioning

confidence: 99%

“…These features make synthetic gene delivery systems very attractive for gene transfer [11]. However, their capacity to transfer NA is still lower in comparison to virus derived vectors [9]. Moreover, the comparison of different synthetic vectors is difficult.…”

Section: Introductionmentioning

confidence: 99%

Synthetic vectors for gene delivery: An overview of their evolution depending on routes of administration.

Belmadi

Midoux

Loyer

et al. 2015

Biotechnology Journal

View full text Add to dashboard Cite

Nucleic acid delivery constitutes an emerging therapeutic strategy to cure various human pathologies. This therapy consists of introducing genetic material into the whole body or isolated cells to correct a cellular abnormality or disfunction. As with any drug, the main objective of nucleic acid delivery is to establish optimal balance between efficacy and tolerance. The methods of administration and the vectors used are selected depending on whether the goal of treatment is the production of an active protein; the replacement of a missing or inactive gene; or the combat of acquired diseases, such as cancer or AIDS. In that sense, synthetic vectors represent a valuable solution because they are well characterized, their structure can be fine tuned, and their potential toxicity can be reduced, since toxicity depends on the composition of the formulations. Here we review various synthetic vectors for gene delivery and address the question of their biodistribution as a function of the route of administration. We highlight the modifications to vectors structure and formulations necessary to overcome the major hurdles limiting the effectiveness of nucleic acid therapies.

show abstract

“…Table 4 lists some examples of the moieties used for active targeting by lipid nanocarriers of RNA. These moieties include receptor substrates, monoclonal antibodies and cell-penetrating peptides [ 55 , 65 - 69 ]. The surface modifications are technically not difficult for lipid-based systems as the phospholipid molecules especially those PEGylated ones can be easily functionalized to provide useful sites for conjugation to the targeting moieties.…”

Section: Strategies To Overcome the Challengesmentioning

confidence: 99%

Lipid-Based Nanocarriers for RNA Delivery

Xue¹,

Guo²,

Wen³

et al. 2015

CPD

175

121

View full text Add to dashboard Cite

RNA-interference (RNAi) agents such as small-interfering RNA (siRNA) and micro-RNA (miRNA) have strong potential as therapeutic agents for the treatment of a broad range of diseases such as malignancies, infections, autoimmune diseases and neurological diseases that are associated with undesirable gene expression. In recent years, several clinical trials of RNAi therapeutics especially siRNAs have been conducted with limited success so far. For systemic administration of these poorly permeable and easily degradable macromolecules, it is obvious that a safe and efficient delivery platform is highly desirable. Because of high biocompatibility, biodegradability and solid track record for clinical use, nanocarriers made of lipids and/or phospholipids have been commonly employed to facilitate RNA delivery. In this article, the key features of the major sub-classes of lipid-based nanocarriers, e.g. liposomes, lipid nanoparticles and lipid nanoemulsions, will be reviewed. Focus of the discussion is on the various challenges researchers face when developing lipid-based RNA nanocarriers, such as the toxicity of cationic lipids and issues related to PEGylated lipids, as well as the strategies employed in tackling these challenges. It is hoped that by understanding more about the pros and cons of these most frequently used RNA delivery systems, the pharmaceutical scientists, biomedical researchers and clinicians will be more successful in overcoming some of the obstacles that currently limit the clinical translation of RNAi therapy.

show abstract

Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells

Cited by 17 publications

References 38 publications

Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery

Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery

Synthetic vectors for gene delivery: An overview of their evolution depending on routes of administration.

Lipid-Based Nanocarriers for RNA Delivery

Contact Info

Product

Resources

About